Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease

References

• Bullock R, Hammond G. Realistic expectations: the management of severe Alzheimer disease. Alzheimer Dis Assoc Disord 2003;17(Suppl 3):S80–5
   PubMedGoogle Scholar
• Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88:1337–42
   PubMed Web of Science ®Google Scholar
• Ibach B, Haen E. Acetylcholinesterase inhibition in Alzheimer's disease. Curr Pharm Des 2004;10:231–51
   PubMed Web of Science ®Google Scholar
• Cummings J, Cole G. Alzheimer disease. JAMA 2002;287:2335–8
   PubMed Web of Science ®Google Scholar
• Weinstock M. Selectivity of cholinesterase inhibition. CNS Drugs 1999;12:307–23
   Web of Science ®Google Scholar
• Davidsson P, Blennow K, Andreasen N, et al. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. Neurosci Lett 2001;300:157–60
   PubMed Web of Science ®Google Scholar
• Barner EL, Gray SL. Donepezil use in Alzheimer disease. Ann Pharmacother 1998;32:70–7
   PubMed Web of Science ®Google Scholar
• Polinsky RJ. Clinical pharmacology of rivastigmine: a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 1998;20:634–47
   PubMed Web of Science ®Google Scholar
• Greig N, Utsuki T, Qian-sheng Y, et al. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Cur Med Res Opin 2001:159–65
   Google Scholar
• Ballard CG. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol 2002; 47:64–70
   PubMed Web of Science ®Google Scholar
• Poirier J. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl 2002;127:6–19
   PubMedGoogle Scholar
• Arendt T, Bruckner MK, Lange M, et al. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development – a study of molecular forms. Neurochem Int 1992;21:381–96
   PubMed Web of Science ®Google Scholar
• Darreh-Shori T, Almkvist O, Guan ZZ, et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 2002;59: 563–72
   Google Scholar
• Tinklenberg J, Newkirk L, Thompson J, et al. Donepezil treatment of Alzheimer's disease patients in California clinical practice: one-year follow-up. Eur Neuropsychopharmacol 2001;11 (Suppl 3):S317–8
   Google Scholar
• Ministero della Sanità. Dipartimento per la valutazione dei medicinali e la farmacovigilanza. Protocollo CRONOS. Protocollo di monitoraggio dei piani di trattamento farmacologico per la malattia di Alzheimer
   Google Scholar
• American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. APA Washington DC; 1994
   Google Scholar
• McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease. Report of the NINDS-ADRDA Work Group. Neurology 1984;34:939–44
   Google Scholar
• Folstein MR, Folstein SE, McHugh PR. ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98
   Google Scholar
• Katz S, Downs TD, Cash HR, et al. Progress in development of the index of ADL. Gerontologist 1970;10:20–30
   PubMed Web of Science ®Google Scholar
• Lawton MP, Brody EM. Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living. Gerontologist 1969;9:179–86
   PubMed Web of Science ®Google Scholar
• Guy W. Clinical Global Impressions (GCI). In: ECDEU Assessment manual for psychopharmacology. US Department of Health and Human Services, Public Health Service, Alcohol Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch: Rockville, MD; 1976, pp. 218–22
   Google Scholar
• Zarit SH, Todd PA, Zarit JM. Subjective burden of husbands and wives as caregivers: a longitudinal study. Gerontologist 1986;26:260–6
   Google Scholar
• Cook RJ, Wei W. Selection effects in randomized trials with count data. Statist Med 2002;21:515–31
   PubMed Web of Science ®Google Scholar
• Auriacombe S, Pere J-J, Loria-Kanza Y, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Cur Med Res Opin 2002;18:129–38
   Google Scholar
• Perry EK, Perry RH, Blessed G. Changes in brain cholinesterase in senile dementia of the Alzheimer type. Neuropathol Appl Neurobiol 1978;4:273–7
   PubMed Web of Science ®Google Scholar
• Costa J, Anand R, Cutler N, et al. Correlation between cognitive effects and level of acetylcholinesterase inhibition in a trial of rivastigmine in Alzheimer patients. Poc Am Psych Assoc 1999;NR:561
   Google Scholar
• Greig N, Utsuki T, Yu Q-S, et al. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin 2001;17:1–7
   Google Scholar
• Edwards KR, Goodman W, Khoury KN, et al. Rapid changeover from donepezil to rivastigmine well tolerated. J Am Geriatr Soc 2001;49:S91–2
   PubMed Web of Science ®Google Scholar
• Etemad B, Anand R, Hartman R. Behavioural and cognitive benefits of rivastigmine in nursing home patients with Alzheimer's disease and related dementias: a 26-week follow-up. Ann Neurol 50;(Suppl 1):S44–5
   Google Scholar
• Messina J, Koumaras J, Hartman R. Treatment with rivastigmine reduces the need for psychotropic medication in patients with Alzheimer's disease residing in long-term care facilities. Poster presented at the 3rd Annual International Meeting for the College of Psychiatric and Neurologic Pharmacists, Washington, DC, USA. 6–9 April 2000
   Google Scholar
• Anxiolytic sedatives hypnotics and antipsychotics. In: Martindale: the complete drug reference. 33rd edn. London: Pharmaceutical Press; 2002, pp. 674–6
   Google Scholar